ID   TENX_HUMAN              Reviewed;        4244 AA.
AC   P22105; P78530; P78531; Q08424; Q08AM0; Q08AM1; Q59GU7; Q5SQD3; Q5ST74;
AC   Q7L8Q4; Q8N4R1; Q9NPK9; Q9UC10; Q9UC11; Q9UC12; Q9UC13; Q9UMG7;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 5.
DT   28-JUN-2023, entry version 235.
DE   RecName: Full=Tenascin-X {ECO:0000305};
DE            Short=TN-X;
DE   AltName: Full=Hexabrachion-like protein;
DE   Flags: Precursor;
GN   Name=TNXB {ECO:0000312|HGNC:HGNC:11976};
GN   Synonyms=HXBL, TNX, TNXB1, TNXB2, XB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM XB-SHORT).
RC   TISSUE=Adrenal gland;
RX   PubMed=8530023; DOI=10.1006/geno.1995.1128;
RA   Tee M.K., Thomson A.A., Bristow J., Miller W.L.;
RT   "Sequences promoting the transcription of the human XA gene overlapping
RT   P450c21A correctly predict the presence of a novel, adrenal-specific,
RT   truncated form of tenascin-X.";
RL   Genomics 28:171-178(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-2518.
RX   PubMed=14656967; DOI=10.1101/gr.1736803;
RA   Xie T., Rowen L., Aguado B., Ahearn M.E., Madan A., Qin S., Campbell R.D.,
RA   Hood L.;
RT   "Analysis of the gene-dense major histocompatibility complex class III
RT   region and its comparison to mouse.";
RL   Genome Res. 13:2621-2636(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ALA-302 AND
RP   GLU-2518.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM XB-SHORT).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-747 (ISOFORM 5), AND NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1605-1862 (ISOFORMS 3/4/5).
RC   TISSUE=Leukocyte;
RX   PubMed=7686164; DOI=10.1083/jcb.122.1.265;
RA   Bristow J., Tee M.K., Gitelman S.E., Mellon S.H., Miller W.L.;
RT   "Tenascin-X: a novel extracellular matrix protein encoded by the human XB
RT   gene overlapping P450c21B.";
RL   J. Cell Biol. 122:265-278(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-23 (ISOFORMS 3/4/5).
RC   TISSUE=Fetal adrenal gland;
RX   PubMed=8923003; DOI=10.1093/hmg/5.11.1749;
RA   Speek M., Barry F., Miller W.L.;
RT   "Alternate promoters and alternate splicing of human tenascin-X, a gene
RT   with 5' and 3' ends buried in other genes.";
RL   Hum. Mol. Genet. 5:1749-1758(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1061-1148; 2521-2607; 2627-2714 AND
RP   2735-2821.
RC   TISSUE=B-cell;
RX   PubMed=1373119; DOI=10.1016/0888-7543(92)90438-x;
RA   Matsumoto K., Arai M., Ishihara N., Ando A., Inoko H., Ikemura T.;
RT   "Cluster of fibronectin type III repeats found in the human major
RT   histocompatibility complex class III region shows the highest homology with
RT   the repeats in an extracellular matrix protein, tenascin.";
RL   Genomics 12:485-491(1992).
RN   [9]
RP   PROTEIN SEQUENCE OF 1399-1407; 1438-1448; 2122-2130; 2438-2446; 2549-2557;
RP   2763-2771; 2782-2799; 2979-2987; 3018-3028; 3193-3201; 3212-3229 AND
RP   3232-3242 (ISOFORMS 3/4/5), PROTEIN SEQUENCE OF 3609-3621 AND 3633-3665
RP   (ISOFORMS XB-SHORT/3/4/5), INTERACTION WITH TROPOELASTIN, AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=17263730; DOI=10.1111/j.1742-4658.2007.05671.x;
RA   Egging D.F., Peeters A.C.T.M., Grebenchtchikov N., Geurts-Moespot A.,
RA   Sweep C.G.J., den Heijer M., Schalkwijk J.;
RT   "Identification and characterization of multiple species of tenascin-X in
RT   human serum.";
RL   FEBS J. 274:1280-1289(2007).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3360-4244 (ISOFORMS 3/4/5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3425-4244 (ISOFORMS 3/4/5).
RX   PubMed=2475872; DOI=10.1073/pnas.86.17.6582;
RA   Morel Y., Bristow J., Gitelman S.E., Miller W.L.;
RT   "Transcript encoded on the opposite strand of the human steroid 21-
RT   hydroxylase/complement component C4 gene locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:6582-6586(1989).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-3920.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH COLLAGEN AND TROPOELASTIN.
RX   PubMed=17033827; DOI=10.1007/s00403-006-0706-9;
RA   Egging D.F., van den Berkmortel F., Taylor G., Bristow J., Schalkwijk J.;
RT   "Interactions of human tenascin-X domains with dermal extracellular matrix
RT   molecules.";
RL   Arch. Dermatol. Res. 298:389-396(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   STRUCTURE BY NMR OF 3654-4024.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the 29th, 31st and 33rd fibronectin type-III domains
RT   of the human tenascin-X.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [16]
RP   INVOLVEMENT IN EDSCLL.
RX   PubMed=11642233; DOI=10.1056/nejmoa002939;
RA   Schalkwijk J., Zweers M.C., Steijlen P.M., Dean W.B., Taylor G.,
RA   van Vlijmen I.M., van Haren B., Miller W.L., Bristow J.;
RT   "A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X
RT   deficiency.";
RL   N. Engl. J. Med. 345:1167-1175(2001).
RN   [17]
RP   VARIANTS EDSCLL TRP-29 AND MET-1108, AND VARIANT ILE-3988.
RX   PubMed=15733269; DOI=10.1111/j.1399-0004.2005.00401.x;
RA   Zweers M.C., Dean W.B., van Kuppevelt T.H., Bristow J., Schalkwijk J.;
RT   "Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome
RT   patients with tenascin-X mutations.";
RL   Clin. Genet. 67:330-334(2005).
RN   [18]
RP   VARIANT EDSCLL CYS-4074.
RX   PubMed=23768946; DOI=10.1016/j.nmd.2013.04.009;
RA   Penisson-Besnier I., Allamand V., Beurrier P., Martin L., Schalkwijk J.,
RA   van Vlijmen-Willems I., Gartioux C., Malfait F., Syx D., Macchi L.,
RA   Marcorelles P., Arbeille B., Croue A., De Paepe A., Dubas F.;
RT   "Compound heterozygous mutations of the TNXB gene cause primary myopathy.";
RL   Neuromuscul. Disord. 23:664-669(2013).
RN   [19]
RP   VARIANTS VUR8 ARG-1244 AND ILE-3212.
RX   PubMed=23620400; DOI=10.1681/asn.2012121148;
RA   Gbadegesin R.A., Brophy P.D., Adeyemo A., Hall G., Gupta I.R., Hains D.,
RA   Bartkowiak B., Rabinovich C.E., Chandrasekharappa S., Homstad A.,
RA   Westreich K., Wu G., Liu Y., Holanda D., Clarke J., Lavin P., Selim A.,
RA   Miller S., Wiener J.S., Ross S.S., Foreman J., Rotimi C., Winn M.P.;
RT   "TNXB mutations can cause vesicoureteral reflux.";
RL   J. Am. Soc. Nephrol. 24:1313-1322(2013).
CC   -!- FUNCTION: Appears to mediate interactions between cells and the
CC       extracellular matrix. Substrate-adhesion molecule that appears to
CC       inhibit cell migration. Accelerates collagen fibril formation. May play
CC       a role in supporting the growth of epithelial tumors.
CC       {ECO:0000269|PubMed:17033827}.
CC   -!- SUBUNIT: Homotrimer. Interacts with type I, III and V collagens and
CC       tropoelastin via its 29th fibronectin type-III domain.
CC       {ECO:0000269|PubMed:17033827, ECO:0000269|PubMed:17263730}.
CC   -!- INTERACTION:
CC       P22105; Q8N9N5: BANP; NbExp=4; IntAct=EBI-2821024, EBI-744695;
CC       P22105-1; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-20753895, EBI-11524452;
CC       P22105-1; P40199: CEACAM6; NbExp=3; IntAct=EBI-20753895, EBI-4314501;
CC       P22105-1; P42858: HTT; NbExp=3; IntAct=EBI-20753895, EBI-466029;
CC       P22105-1; P78424: POU6F2; NbExp=3; IntAct=EBI-20753895, EBI-12029004;
CC       P22105-1; Q96PF1: TGM7; NbExp=3; IntAct=EBI-20753895, EBI-12029034;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=4;
CC         IsoId=P22105-3; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P22105-1; Sequence=VSP_059794;
CC       Name=XB-short; Synonyms=2;
CC         IsoId=P22105-2; Sequence=VSP_059792;
CC       Name=5;
CC         IsoId=P22105-4; Sequence=VSP_059793, VSP_059794;
CC   -!- TISSUE SPECIFICITY: Highly expressed in fetal adrenal, in fetal testis,
CC       fetal smooth, striated and cardiac muscle. Isoform XB-short is only
CC       expressed in the adrenal gland.
CC   -!- DEVELOPMENTAL STAGE: Expression levels are lower in adults than in
CC       children. {ECO:0000269|PubMed:17263730}.
CC   -!- DISEASE: Ehlers-Danlos syndrome, classic-like (EDSCLL) [MIM:606408]: A
CC       form of Ehlers-Danlos syndrome, a group of connective tissue disorders
CC       characterized by skin hyperextensibility, articular hypermobility, and
CC       tissue fragility. EDSCLL patients lack atrophic scars, a major
CC       diagnostic criteria for classic Ehlers-Danlos syndrome. Delayed wound
CC       healing is only present in a subset of patients. EDSCLL inheritance is
CC       autosomal recessive. {ECO:0000269|PubMed:11642233,
CC       ECO:0000269|PubMed:15733269, ECO:0000269|PubMed:23768946}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Vesicoureteral reflux 8 (VUR8) [MIM:615963]: A disease
CC       belonging to the group of congenital anomalies of the kidney and
CC       urinary tract. It is characterized by the reflux of urine from the
CC       bladder into the ureters and sometimes into the kidneys, and is a risk
CC       factor for urinary tract infections. Primary disease results from a
CC       developmental defect of the ureterovesical junction. In combination
CC       with intrarenal reflux, the resulting inflammatory reaction may result
CC       in renal injury or scarring, also called reflux nephropathy. Extensive
CC       renal scarring impairs renal function and may predispose patients to
CC       hypertension, proteinuria, renal insufficiency and end-stage renal
CC       disease. {ECO:0000269|PubMed:23620400}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 4]: May be due to competing acceptor splice
CC       site in exon 24.
CC   -!- MISCELLANEOUS: [Isoform 5]: May be due to competing donor splice site
CC       in exon 1. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the tenascin family. {ECO:0000305}.
CC   -!- CAUTION: There are two genes for TN-X: TNXA and TNXB. TNXA can
CC       sometimes recombine with TNXB. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB47488.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAB67981.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAB89296.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U24488; AAB41287.1; -; mRNA.
DR   EMBL; AF019413; AAB67981.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; U89337; AAB47488.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL049547; CAB89296.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL049547; CAB89300.1; -; Genomic_DNA.
DR   EMBL; AL645922; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662828; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662884; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL772248; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03574.1; -; Genomic_DNA.
DR   EMBL; BC033740; AAH33740.1; -; mRNA.
DR   EMBL; BC125114; AAI25115.1; -; mRNA.
DR   EMBL; BC125115; AAI25116.1; -; mRNA.
DR   EMBL; BC130037; AAI30038.1; -; mRNA.
DR   EMBL; X71923; CAA50739.1; -; mRNA.
DR   EMBL; Y13782; CAA74109.1; -; mRNA.
DR   EMBL; Y13783; CAA74110.1; -; Genomic_DNA.
DR   EMBL; U52696; AAC50889.1; -; mRNA.
DR   EMBL; AB209012; BAD92249.1; -; mRNA.
DR   EMBL; M25813; AAA35884.1; -; mRNA.
DR   CCDS; CCDS4736.1; -. [P22105-2]
DR   CCDS; CCDS93886.1; -. [P22105-3]
DR   PIR; A40701; A40701.
DR   PIR; A42175; A42175.
DR   PIR; B42175; B42175.
DR   PIR; D42175; D42175.
DR   RefSeq; NP_061978.6; NM_019105.6. [P22105-1]
DR   RefSeq; NP_115859.2; NM_032470.3. [P22105-2]
DR   PDB; 2CUH; NMR; -; A=3845-3946.
DR   PDB; 2CUI; NMR; -; A=3654-3752.
DR   PDB; 2CUM; NMR; -; A=3933-4024.
DR   PDBsum; 2CUH; -.
DR   PDBsum; 2CUI; -.
DR   PDBsum; 2CUM; -.
DR   SMR; P22105; -.
DR   BioGRID; 113001; 45.
DR   ComplexPortal; CPX-1014; Tenascin-X complex.
DR   IntAct; P22105; 14.
DR   MINT; P22105; -.
DR   STRING; 9606.ENSP00000407685; -.
DR   GlyConnect; 1794; 7 N-Linked glycans (3 sites).
DR   GlyCosmos; P22105; 43 sites, 13 glycans.
DR   GlyGen; P22105; 44 sites, 6 N-linked glycans (2 sites), 8 O-linked glycans (39 sites).
DR   iPTMnet; P22105; -.
DR   PhosphoSitePlus; P22105; -.
DR   SwissPalm; P22105; -.
DR   BioMuta; TNXB; -.
DR   DMDM; 290457668; -.
DR   CPTAC; non-CPTAC-2701; -.
DR   EPD; P22105; -.
DR   jPOST; P22105; -.
DR   MassIVE; P22105; -.
DR   MaxQB; P22105; -.
DR   PaxDb; P22105; -.
DR   PeptideAtlas; P22105; -.
DR   ProteomicsDB; 53963; -. [P22105-1]
DR   ProteomicsDB; 53964; -. [P22105-2]
DR   ProteomicsDB; 53965; -. [P22105-3]
DR   Antibodypedia; 3947; 260 antibodies from 31 providers.
DR   DNASU; 7148; -.
DR   Ensembl; ENST00000375244.7; ENSP00000364393.3; ENSG00000168477.20. [P22105-3]
DR   Ensembl; ENST00000451343.4; ENSP00000407685.1; ENSG00000168477.20. [P22105-2]
DR   Ensembl; ENST00000546684.2; ENSP00000447694.2; ENSG00000236236.9.
DR   Ensembl; ENST00000550539.2; ENSP00000448326.2; ENSG00000229353.10.
DR   Ensembl; ENST00000644971.2; ENSP00000496448.1; ENSG00000168477.20. [P22105-3]
DR   GeneID; 7148; -.
DR   KEGG; hsa:7148; -.
DR   MANE-Select; ENST00000644971.2; ENSP00000496448.1; NM_001365276.2; NP_001352205.1.
DR   UCSC; uc003nzg.1; human. [P22105-3]
DR   AGR; HGNC:11976; -.
DR   CTD; 7148; -.
DR   DisGeNET; 7148; -.
DR   GeneCards; TNXB; -.
DR   GeneReviews; TNXB; -.
DR   HGNC; HGNC:11976; TNXB.
DR   HPA; ENSG00000168477; Tissue enhanced (adrenal).
DR   MalaCards; TNXB; -.
DR   MIM; 600985; gene.
DR   MIM; 606408; phenotype.
DR   MIM; 615963; phenotype.
DR   neXtProt; NX_P22105; -.
DR   OpenTargets; ENSG00000168477; -.
DR   Orphanet; 230839; Classical-like Ehlers-Danlos syndrome type 1.
DR   Orphanet; 289365; Familial vesicoureteral reflux.
DR   PharmGKB; PA36662; -.
DR   VEuPathDB; HostDB:ENSG00000168477; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   GeneTree; ENSGT00940000155565; -.
DR   HOGENOM; CLU_026380_0_0_1; -.
DR   InParanoid; P22105; -.
DR   OrthoDB; 4251562at2759; -.
DR   TreeFam; TF329915; -.
DR   PathwayCommons; P22105; -.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   SignaLink; P22105; -.
DR   BioGRID-ORCS; 7148; 16 hits in 1152 CRISPR screens.
DR   ChiTaRS; TNXB; human.
DR   EvolutionaryTrace; P22105; -.
DR   GeneWiki; Tenascin_X; -.
DR   GenomeRNAi; 7148; -.
DR   Pharos; P22105; Tbio.
DR   PRO; PR:P22105; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P22105; protein.
DR   Bgee; ENSG00000168477; Expressed in apex of heart and 96 other tissues.
DR   ExpressionAtlas; P22105; baseline and differential.
DR   Genevisible; P22105; HS.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; NAS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; HDA:BHF-UCL.
DR   GO; GO:0090733; C:tenascin complex; ISO:ComplexPortal.
DR   GO; GO:0005518; F:collagen binding; IEA:Ensembl.
DR   GO; GO:0098633; F:collagen fibril binding; IDA:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; ISS:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; ISS:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; ISS:UniProtKB.
DR   GO; GO:0098609; P:cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0030199; P:collagen fibril organization; IEA:Ensembl.
DR   GO; GO:0032963; P:collagen metabolic process; IMP:UniProtKB.
DR   GO; GO:0048251; P:elastic fiber assembly; IMP:UniProtKB.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IBA:GO_Central.
DR   GO; GO:1905935; P:positive regulation of cell fate determination; NAS:ComplexPortal.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:ComplexPortal.
DR   GO; GO:1904028; P:positive regulation of collagen fibril organization; IDA:ComplexPortal.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISO:ComplexPortal.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISO:ComplexPortal.
DR   GO; GO:1901390; P:positive regulation of transforming growth factor beta activation; ISO:ComplexPortal.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; ISO:ComplexPortal.
DR   GO; GO:1900748; P:positive regulation of vascular endothelial growth factor signaling pathway; ISO:ComplexPortal.
DR   GO; GO:0030155; P:regulation of cell adhesion; ISO:ComplexPortal.
DR   GO; GO:0045595; P:regulation of cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0030334; P:regulation of cell migration; ISO:ComplexPortal.
DR   GO; GO:0043506; P:regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   CDD; cd00054; EGF_CA; 5.
DR   CDD; cd00063; FN3; 31.
DR   CDD; cd00087; FReD; 1.
DR   Gene3D; 3.90.215.10; Gamma Fibrinogen, chain A, domain 1; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 31.
DR   Gene3D; 2.10.25.10; Laminin; 17.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR041161; EGF_Tenascin.
DR   InterPro; IPR036056; Fibrinogen-like_C.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   PANTHER; PTHR46708; TENASCIN; 1.
DR   PANTHER; PTHR46708:SF3; TENASCIN-X; 1.
DR   Pfam; PF07974; EGF_2; 2.
DR   Pfam; PF18720; EGF_Tenascin; 10.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   Pfam; PF00041; fn3; 31.
DR   SMART; SM00181; EGF; 18.
DR   SMART; SM00186; FBG; 1.
DR   SMART; SM00060; FN3; 32.
DR   SUPFAM; SSF56496; Fibrinogen C-terminal domain-like; 1.
DR   SUPFAM; SSF49265; Fibronectin type III; 29.
DR   PROSITE; PS00022; EGF_1; 18.
DR   PROSITE; PS01186; EGF_2; 19.
DR   PROSITE; PS50026; EGF_3; 8.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
DR   PROSITE; PS50853; FN3; 32.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Coiled coil;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   EGF-like domain; Ehlers-Danlos syndrome; Extracellular matrix;
KW   Glycoprotein; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..4244
FT                   /note="Tenascin-X"
FT                   /id="PRO_0000007751"
FT   DOMAIN          156..168
FT                   /note="EGF-like 1; incomplete"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          183..213
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          214..244
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          245..275
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          276..306
FT                   /note="EGF-like 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          307..337
FT                   /note="EGF-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          338..368
FT                   /note="EGF-like 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          369..399
FT                   /note="EGF-like 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          400..430
FT                   /note="EGF-like 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          431..461
FT                   /note="EGF-like 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          462..492
FT                   /note="EGF-like 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          493..523
FT                   /note="EGF-like 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          524..554
FT                   /note="EGF-like 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          555..585
FT                   /note="EGF-like 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          586..616
FT                   /note="EGF-like 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          617..647
FT                   /note="EGF-like 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          648..679
FT                   /note="EGF-like 17"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          684..714
FT                   /note="EGF-like 18"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          715..746
FT                   /note="EGF-like 19"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          959..1051
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1064..1153
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1161..1249
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1263..1352
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1374..1468
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1476..1572
FT                   /note="Fibronectin type-III 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1574..1669
FT                   /note="Fibronectin type-III 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1674..1764
FT                   /note="Fibronectin type-III 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1778..1868
FT                   /note="Fibronectin type-III 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1883..1971
FT                   /note="Fibronectin type-III 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1989..2089
FT                   /note="Fibronectin type-III 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2097..2185
FT                   /note="Fibronectin type-III 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2196..2296
FT                   /note="Fibronectin type-III 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2305..2398
FT                   /note="Fibronectin type-III 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2408..2502
FT                   /note="Fibronectin type-III 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2519..2617
FT                   /note="Fibronectin type-III 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2625..2723
FT                   /note="Fibronectin type-III 17"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2733..2840
FT                   /note="Fibronectin type-III 18"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2841..2939
FT                   /note="Fibronectin type-III 19"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2949..3042
FT                   /note="Fibronectin type-III 20"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3062..3153
FT                   /note="Fibronectin type-III 21"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3168..3260
FT                   /note="Fibronectin type-III 22"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3264..3355
FT                   /note="Fibronectin type-III 23"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3357..3446
FT                   /note="Fibronectin type-III 24"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3451..3544
FT                   /note="Fibronectin type-III 25"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3553..3647
FT                   /note="Fibronectin type-III 26"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3657..3754
FT                   /note="Fibronectin type-III 27"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3758..3847
FT                   /note="Fibronectin type-III 28"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3848..3934
FT                   /note="Fibronectin type-III 29"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          3935..4025
FT                   /note="Fibronectin type-III 30"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          4021..4236
FT                   /note="Fibrinogen C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   REGION          27..57
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          169..189
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          926..956
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1340..1372
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1752..1777
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1968..1990
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2281..2304
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2495..2542
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2824..2847
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2933..2969
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3536..3559
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3636..3662
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1666..1668
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        940..956
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        3643..3662
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        31
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3855
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3908
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3920
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        4095
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        187..197
FT                   /evidence="ECO:0000250"
FT   DISULFID        191..202
FT                   /evidence="ECO:0000250"
FT   DISULFID        204..213
FT                   /evidence="ECO:0000250"
FT   DISULFID        218..228
FT                   /evidence="ECO:0000250"
FT   DISULFID        222..233
FT                   /evidence="ECO:0000250"
FT   DISULFID        235..244
FT                   /evidence="ECO:0000250"
FT   DISULFID        249..259
FT                   /evidence="ECO:0000250"
FT   DISULFID        253..264
FT                   /evidence="ECO:0000250"
FT   DISULFID        266..275
FT                   /evidence="ECO:0000250"
FT   DISULFID        280..290
FT                   /evidence="ECO:0000250"
FT   DISULFID        284..295
FT                   /evidence="ECO:0000250"
FT   DISULFID        297..306
FT                   /evidence="ECO:0000250"
FT   DISULFID        311..321
FT                   /evidence="ECO:0000250"
FT   DISULFID        315..326
FT                   /evidence="ECO:0000250"
FT   DISULFID        328..337
FT                   /evidence="ECO:0000250"
FT   DISULFID        342..352
FT                   /evidence="ECO:0000250"
FT   DISULFID        346..357
FT                   /evidence="ECO:0000250"
FT   DISULFID        359..368
FT                   /evidence="ECO:0000250"
FT   DISULFID        373..383
FT                   /evidence="ECO:0000250"
FT   DISULFID        377..388
FT                   /evidence="ECO:0000250"
FT   DISULFID        390..399
FT                   /evidence="ECO:0000250"
FT   DISULFID        404..414
FT                   /evidence="ECO:0000250"
FT   DISULFID        408..419
FT                   /evidence="ECO:0000250"
FT   DISULFID        421..430
FT                   /evidence="ECO:0000250"
FT   DISULFID        435..445
FT                   /evidence="ECO:0000250"
FT   DISULFID        439..450
FT                   /evidence="ECO:0000250"
FT   DISULFID        452..461
FT                   /evidence="ECO:0000250"
FT   DISULFID        466..476
FT                   /evidence="ECO:0000250"
FT   DISULFID        470..481
FT                   /evidence="ECO:0000250"
FT   DISULFID        483..492
FT                   /evidence="ECO:0000250"
FT   DISULFID        497..507
FT                   /evidence="ECO:0000250"
FT   DISULFID        501..512
FT                   /evidence="ECO:0000250"
FT   DISULFID        514..523
FT                   /evidence="ECO:0000250"
FT   DISULFID        528..538
FT                   /evidence="ECO:0000250"
FT   DISULFID        532..543
FT                   /evidence="ECO:0000250"
FT   DISULFID        545..554
FT                   /evidence="ECO:0000250"
FT   DISULFID        559..569
FT                   /evidence="ECO:0000250"
FT   DISULFID        563..574
FT                   /evidence="ECO:0000250"
FT   DISULFID        576..585
FT                   /evidence="ECO:0000250"
FT   DISULFID        590..600
FT                   /evidence="ECO:0000250"
FT   DISULFID        594..605
FT                   /evidence="ECO:0000250"
FT   DISULFID        607..616
FT                   /evidence="ECO:0000250"
FT   DISULFID        621..631
FT                   /evidence="ECO:0000250"
FT   DISULFID        625..636
FT                   /evidence="ECO:0000250"
FT   DISULFID        638..647
FT                   /evidence="ECO:0000250"
FT   DISULFID        652..662
FT                   /evidence="ECO:0000250"
FT   DISULFID        656..667
FT                   /evidence="ECO:0000250"
FT   DISULFID        669..678
FT                   /evidence="ECO:0000250"
FT   DISULFID        688..698
FT                   /evidence="ECO:0000250"
FT   DISULFID        692..703
FT                   /evidence="ECO:0000250"
FT   DISULFID        705..714
FT                   /evidence="ECO:0000250"
FT   DISULFID        719..729
FT                   /evidence="ECO:0000250"
FT   DISULFID        723..734
FT                   /evidence="ECO:0000250"
FT   DISULFID        736..745
FT                   /evidence="ECO:0000250"
FT   DISULFID        4030..4060
FT                   /evidence="ECO:0000250"
FT   DISULFID        4182..4195
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..3571
FT                   /note="Missing (in isoform XB-short)"
FT                   /id="VSP_059792"
FT   VAR_SEQ         135
FT                   /note="G -> GEQG (in isoform 5)"
FT                   /id="VSP_059793"
FT   VAR_SEQ         2823..2825
FT                   /note="APE -> E (in isoform 3 and isoform 5)"
FT                   /id="VSP_059794"
FT   VARIANT         29
FT                   /note="R -> W (in EDSCLL; dbSNP:rs368512272)"
FT                   /evidence="ECO:0000269|PubMed:15733269"
FT                   /id="VAR_046499"
FT   VARIANT         302
FT                   /note="T -> A (in dbSNP:rs1150752)"
FT                   /evidence="ECO:0000269|PubMed:14574404"
FT                   /id="VAR_044347"
FT   VARIANT         511
FT                   /note="R -> H (in dbSNP:rs204896)"
FT                   /id="VAR_021908"
FT   VARIANT         641
FT                   /note="G -> C (in dbSNP:rs17201609)"
FT                   /id="VAR_055781"
FT   VARIANT         650
FT                   /note="R -> H (in dbSNP:rs17201602)"
FT                   /id="VAR_055782"
FT   VARIANT         873
FT                   /note="S -> A (in dbSNP:rs204900)"
FT                   /id="VAR_055783"
FT   VARIANT         1108
FT                   /note="V -> M (in EDSCLL; dbSNP:rs121912575)"
FT                   /evidence="ECO:0000269|PubMed:15733269"
FT                   /id="VAR_046500"
FT   VARIANT         1161
FT                   /note="H -> R (in dbSNP:rs185819)"
FT                   /id="VAR_024270"
FT   VARIANT         1244
FT                   /note="T -> R (in VUR8)"
FT                   /evidence="ECO:0000269|PubMed:23620400"
FT                   /id="VAR_072580"
FT   VARIANT         1905
FT                   /note="E -> K (in dbSNP:rs17207923)"
FT                   /id="VAR_059276"
FT   VARIANT         2301
FT                   /note="P -> H (in dbSNP:rs2269428)"
FT                   /id="VAR_020170"
FT   VARIANT         2363
FT                   /note="P -> H (in dbSNP:rs2269428)"
FT                   /id="VAR_055784"
FT   VARIANT         2412
FT                   /note="P -> L (in dbSNP:rs12524664)"
FT                   /id="VAR_059277"
FT   VARIANT         2495
FT                   /note="G -> S (in dbSNP:rs2269429)"
FT                   /id="VAR_020171"
FT   VARIANT         2518
FT                   /note="G -> E (in dbSNP:rs1009382)"
FT                   /evidence="ECO:0000269|PubMed:14574404,
FT                   ECO:0000269|PubMed:14656967"
FT                   /id="VAR_020172"
FT   VARIANT         3212
FT                   /note="V -> I (in VUR8; shows significantly impaired
FT                   migration in a wound-healing assay; associated with
FT                   decreased expression of phosphorylated PTK2 protein;
FT                   dbSNP:rs1473257039)"
FT                   /evidence="ECO:0000269|PubMed:23620400"
FT                   /id="VAR_072581"
FT   VARIANT         3988
FT                   /note="L -> I (in dbSNP:rs7742632)"
FT                   /evidence="ECO:0000269|PubMed:15733269"
FT                   /id="VAR_046501"
FT   VARIANT         4074
FT                   /note="R -> C (in EDSCLL; dbSNP:rs587777682)"
FT                   /evidence="ECO:0000269|PubMed:23768946"
FT                   /id="VAR_072582"
FT   CONFLICT        3791
FT                   /note="Q -> L (in Ref. 5; AAH33740)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3877
FT                   /note="V -> I (in Ref. 5; AAI25115/AAI25116 and 10;
FT                   BAD92249)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3974
FT                   /note="N -> T (in Ref. 5; AAI25115/AAI25116 and 10;
FT                   BAD92249)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3993
FT                   /note="P -> G (in Ref. 1; AAB41287 and 11; AAA35884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4004
FT                   /note="M -> T (in Ref. 5; AAI25116 and 10; BAD92249)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4057
FT                   /note="N -> I (in Ref. 5; AAI25115)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4118
FT                   /note="M -> I (in Ref. 1; AAB41287 and 11; AAA35884)"
FT                   /evidence="ECO:0000305"
FT   STRAND          3662..3665
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3671..3674
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3683..3690
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3695..3697
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3707..3712
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3717..3720
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3728..3736
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3738..3750
FT                   /evidence="ECO:0007829|PDB:2CUI"
FT   STRAND          3849..3852
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3857..3859
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3861..3866
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3873..3880
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3882..3884
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3887..3892
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3896..3900
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3905..3917
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3925..3931
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   TURN            3936..3938
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3939..3941
FT                   /evidence="ECO:0007829|PDB:2CUH"
FT   STRAND          3949..3954
FT                   /evidence="ECO:0007829|PDB:2CUM"
FT   STRAND          3961..3968
FT                   /evidence="ECO:0007829|PDB:2CUM"
FT   STRAND          3974..3979
FT                   /evidence="ECO:0007829|PDB:2CUM"
FT   STRAND          3984..3988
FT                   /evidence="ECO:0007829|PDB:2CUM"
FT   STRAND          3996..4005
FT                   /evidence="ECO:0007829|PDB:2CUM"
FT   STRAND          4013..4018
FT                   /evidence="ECO:0007829|PDB:2CUM"
SQ   SEQUENCE   4244 AA;  458388 MW;  45A3D29FDF133DBA CRC64;
     MMPAQYALTS SLVLLVLLST ARAGPFSSRS NVTLPAPRPP PQPGGHTVGA GVGSPSSQLY
     EHTVEGGEKQ VVFTHRINLP PSTGCGCPPG TEPPVLASEV QALRVRLEIL EELVKGLKEQ
     CTGGCCPASA QAGTGQTDVR TLCSLHGVFD LSRCTCSCEP GWGGPTCSDP TDAEIPPSSP
     PSASGSCPDD CNDQGRCVRG RCVCFPGYTG PSCGWPSCPG DCQGRGRCVQ GVCVCRAGFS
     GPDCSQRSCP RGCSQRGRCE GGRCVCDPGY TGDDCGMRSC PRGCSQRGRC ENGRCVCNPG
     YTGEDCGVRS CPRGCSQRGR CKDGRCVCDP GYTGEDCGTR SCPWDCGEGG RCVDGRCVCW
     PGYTGEDCST RTCPRDCRGR GRCEDGECIC DTGYSGDDCG VRSCPGDCNQ RGRCEDGRCV
     CWPGYTGTDC GSRACPRDCR GRGRCENGVC VCNAGYSGED CGVRSCPGDC RGRGRCESGR
     CMCWPGYTGR DCGTRACPGD CRGRGRCVDG RCVCNPGFTG EDCGSRRCPG DCRGHGLCED
     GVCVCDAGYS GEDCSTRSCP GGCRGRGQCL DGRCVCEDGY SGEDCGVRQC PNDCSQHGVC
     QDGVCICWEG YVSEDCSIRT CPSNCHGRGR CEEGRCLCDP GYTGPTCATR MCPADCRGRG
     RCVQGVCLCH VGYGGEDCGQ EEPPASACPG GCGPRELCRA GQCVCVEGFR GPDCAIQTCP
     GDCRGRGECH DGSCVCKDGY AGEDCGEEVP TIEGMRMHLL EETTVRTEWT PAPGPVDAYE
     IQFIPTTEGA SPPFTARVPS SASAYDQRGL APGQEYQVTV RALRGTSWGL PASKTITTMI
     DGPQDLRVVA VTPTTLELGW LRPQAEVDRF VVSYVSAGNQ RVRLEVPPEA DGTLLTDLMP
     GVEYVVTVTA ERGRAVSYPA SVRANTGSSP LGLLGTTDEP PPSGPSTTQG AQAPLLQQRP
     QELGELRVLG RDETGRLRVV WTAQPDTFAY FQLRMRVPEG PGAHEEVLPG DVRQALVPPP
     PPGTPYELSL HGVPPGGKPS DPIIYQGIMD KDEEKPGKSS GPPRLGELTV TDRTSDSLLL
     RWTVPEGEFD SFVIQYKDRD GQPQVVPVEG PQRSAVITSL DPGRKYKFVL YGFVGKKRHG
     PLVAEAKILP QSDPSPGTPP HLGNLWVTDP TPDSLHLSWT VPEGQFDTFM VQYRDRDGRP
     QVVPVEGPER SFVVSSLDPD HKYRFTLFGI ANKKRYGPLT ADGTTAPERK EEPPRPEFLE
     QPLLGELTVT GVTPDSLRLS WTVAQGPFDS FMVQYKDAQG QPQAVPVAGD ENEVTVPGLD
     PDRKYKMNLY GLRGRQRVGP ESVVAKTAPQ EDVDETPSPT ELGTEAPESP EEPLLGELTV
     TGSSPDSLSL FWTVPQGSFD SFTVQYKDRD GRPRAVRVGG KESEVTVGGL EPGHKYKMHL
     YGLHEGQRVG PVSAVGVTAP QQEETPPATE SPLEPRLGEL TVTDVTPNSV GLSWTVPEGQ
     FDSFIVQYKD KDGQPQVVPV AADQREVTVY NLEPERKYKM NMYGLHDGQR MGPLSVVIVT
     APLPPAPATE ASKPPLEPRL GELTVTDITP DSVGLSWTVP EGEFDSFVVQ YKDRDGQPQV
     VPVAADQREV TIPDLEPSRK YKFLLFGIQD GKRRSPVSVE AKTVARGDAS PGAPPRLGEL
     WVTDPTPDSL RLSWTVPEGQ FDSFVVQFKD KDGPQVVPVE GHERSVTVTP LDAGRKYRFL
     LYGLLGKKRH GPLTADGTTE ARSAMDDTGT KRPPKPRLGE ELQVTTVTQN SVGLSWTVPE
     GQFDSFVVQY KDRDGQPQVV PVEGSLREVS VPGLDPAHRY KLLLYGLHHG KRVGPISAVA
     ITAGREETET ETTAPTPPAP EPHLGELTVE EATSHTLHLS WMVTEGEFDS FEIQYTDRDG
     QLQMVRIGGD RNDITLSGLE SDHRYLVTLY GFSDGKHVGP VHVEALTVPE EEKPSEPPTA
     TPEPPIKPRL GELTVTDATP DSLSLSWTVP EGQFDHFLVQ YRNGDGQPKA VRVPGHEEGV
     TISGLEPDHK YKMNLYGFHG GQRMGPVSVV GVTAAEEETP SPTEPSMEAP EPAEEPLLGE
     LTVTGSSPDS LSLSWTVPQG RFDSFTVQYK DRDGRPQVVR VGGEESEVTV GGLEPGRKYK
     MHLYGLHEGR RVGPVSAVGV TAPEEESPDA PLAKLRLGQM TVRDITSDSL SLSWTVPEGQ
     FDHFLVQFKN GDGQPKAVRV PGHEDGVTIS GLEPDHKYKM NLYGFHGGQR VGPVSAVGLT
     APGKDEEMAP ASTEPPTPEP PIKPRLEELT VTDATPDSLS LSWTVPEGQF DHFLVQYKNG
     DGQPKATRVP GHEDRVTISG LEPDNKYKMN LYGFHGGQRV GPVSAIGVTA AEEETPSPTE
     PSMEAPEPPE EPLLGELTVT GSSPDSLSLS WTVPQGRFDS FTVQYKDRDG RPQVVRVGGE
     ESEVTVGGLE PGRKYKMHLY GLHEGRRVGP VSTVGVTAPQ EDVDETPSPT EPGTEAPGPP
     EEPLLGELTV TGSSPDSLSL SWTVPQGRFD SFTVQYKDRD GRPQAVRVGG QESKVTVRGL
     EPGRKYKMHL YGLHEGRRLG PVSAVGVTED EAETTQAVPT MTPEPPIKPR LGELTMTDAT
     PDSLSLSWTV PEGQFDHFLV QYRNGDGQPK AVRVPGHEDG VTISGLEPDH KYKMNLYGFH
     GGQRVGPISV IGVTAAEEET PSPTELSTEA PEPPEEPLLG ELTVTGSSPD SLSLSWTIPQ
     GHFDSFTVQY KDRDGRPQVM RVRGEESEVT VGGLEPGRKY KMHLYGLHEG RRVGPVSTVG
     VTAPEDEAET TQAVPTTTPE PPNKPRLGEL TVTDATPDSL SLSWMVPEGQ FDHFLVQYRN
     GDGQPKVVRV PGHEDGVTIS GLEPDHKYKM NLYGFHGGQR VGPISVIGVT AAEEETPAPT
     EPSTEAPEPP EEPLLGELTV TGSSPDSLSL SWTIPQGRFD SFTVQYKDRD GRPQVVRVRG
     EESEVTVGGL EPGCKYKMHL YGLHEGQRVG PVSAVGVTAP KDEAETTQAV PTMTPEPPIK
     PRLGELTVTD ATPDSLSLSW MVPEGQFDHF LVQYRNGDGQ PKAVRVPGHE DGVTISGLEP
     DHKYKMNLYG FHGGQRVGPV SAIGVTEEET PSPTEPSTEA PEAPEEPLLG ELTVTGSSPD
     SLSLSWTVPQ GRFDSFTVQY KDRDGQPQVV RVRGEESEVT VGGLEPGRKY KMHLYGLHEG
     QRVGPVSTVG ITAPLPTPLP VEPRLGELAV AAVTSDSVGL SWTVAQGPFD SFLVQYRDAQ
     GQPQAVPVSG DLRAVAVSGL DPARKYKFLL FGLQNGKRHG PVPVEARTAP DTKPSPRLGE
     LTVTDATPDS VGLSWTVPEG EFDSFVVQYK DKDGRLQVVP VAANQREVTV QGLEPSRKYR
     FLLYGLSGRK RLGPISADST TAPLEKELPP HLGELTVAEE TSSSLRLSWT VAQGPFDSFV
     VQYRDTDGQP RAVPVAADQR TVTVEDLEPG KKYKFLLYGL LGGKRLGPVS ALGMTAPEED
     TPAPELAPEA PEPPEEPRLG VLTVTDTTPD SMRLSWSVAQ GPFDSFVVQY EDTNGQPQAL
     LVDGDQSKIL ISGLEPSTPY RFLLYGLHEG KRLGPLSAEG TTGLAPAGQT SEESRPRLSQ
     LSVTDVTTSS LRLNWEAPPG AFDSFLLRFG VPSPSTLEPH PRPLLQRELM VPGTRHSAVL
     RDLRSGTLYS LTLYGLRGPH KADSIQGTAR TLSPVLESPR DLQFSEIRET SAKVNWMPPP
     SRADSFKVSY QLADGGEPQS VQVDGQARTQ KLQGLIPGAR YEVTVVSVRG FEESEPLTGF
     LTTVPDGPTQ LRALNLTEGF AVLHWKPPQN PVDTYDVQVT APGAPPLQAE TPGSAVDYPL
     HDLVLHTNYT ATVRGLRGPN LTSPASITFT TGLEAPRDLE AKEVTPRTAL LTWTEPPVRP
     AGYLLSFHTP GGQNQEILLP GGITSHQLLG LFPSTSYNAR LQAMWGQSLL PPVSTSFTTG
     GLRIPFPRDC GEEMQNGAGA SRTSTIFLNG NRERPLNVFC DMETDGGGWL VFQRRMDGQT
     DFWRDWEDYA HGFGNISGEF WLGNEALHSL TQAGDYSMRV DLRAGDEAVF AQYDSFHVDS
     AAEYYRLHLE GYHGTAGDSM SYHSGSVFSA RDRDPNSLLI SCAVSYRGAW WYRNCHYANL
     NGLYGSTVDH QGVSWYHWKG FEFSVPFTEM KLRPRNFRSP AGGG
//
